PE20120535A1 - 3-amino-2-mercaptoquinolina sustituida como modulador de kcnq2/3 - Google Patents

3-amino-2-mercaptoquinolina sustituida como modulador de kcnq2/3

Info

Publication number
PE20120535A1
PE20120535A1 PE2011001564A PE2011001564A PE20120535A1 PE 20120535 A1 PE20120535 A1 PE 20120535A1 PE 2011001564 A PE2011001564 A PE 2011001564A PE 2011001564 A PE2011001564 A PE 2011001564A PE 20120535 A1 PE20120535 A1 PE 20120535A1
Authority
PE
Peru
Prior art keywords
mercaptoquinoline
amino
quinolin
acetamide
alkyl
Prior art date
Application number
PE2011001564A
Other languages
English (en)
Inventor
Sven Kuhnert
Gregor Bahrenberg
Wolfgang Schroder
Original Assignee
Gruenenthal Chemie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Chemie filed Critical Gruenenthal Chemie
Publication of PE20120535A1 publication Critical patent/PE20120535A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

REFERIDA A UN COMPUESTO DERIVADO DE 3-AMINO-2-MERCAPTOQUINOLINA DE FORMULA (1), DONDE m ES 0 O 1; n ES UN ENTERO DE 0 A 4; R1, R2, R3, R4, R5, R6a Y R6b SON H, F, Cl, NO2, CN,OH, ENTRE OTROS; Y ES O O NR9; R9 ES H, ALQUILO C1-C4, ENTRE OTROS; R7 ES ALQUILO C1-C10, HETEROALQUILO C2-C10, ENTRE OTROS; R8 ES ALQUILO C1-C10, HETEROALQUILO C2-C10, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 2-CICLOHEXIL-N-(2-(2-(FENILSULFONIL)ETILTIO)QUINOLIN-3-IL)ACETAMIDA, N-(2-(2-(FENILSULFONIL)ETILTIO)QUINOLIN-3-IL)-2-(TIOFEN-2-IL)ACETAMIDA, N-(2-(PENTILTIO)QUINOLIN-3-IL)-2-(TIOFEN-2-IL)ACETAMIDA, ENTRE OTROS. DICHOS COMPUESTOS TIENEN ACTIVIDAD SOBRE LOS CANALES DE POTASIO HETEROMERICOS DEL SUBTIPO MOLECULAR KCNQ2/3 Y SON UTILES EN EL TRATAMIENTO DE DOLORES AGUDOS, CRONICOS, NEUROPATICOS, MUSCULARES E INFLAMATORIOS, EPILEPSIA, MIGRANA, ENTRE OTROS
PE2011001564A 2009-03-10 2010-03-09 3-amino-2-mercaptoquinolina sustituida como modulador de kcnq2/3 PE20120535A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09003431 2009-03-10

Publications (1)

Publication Number Publication Date
PE20120535A1 true PE20120535A1 (es) 2012-05-09

Family

ID=40591941

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011001564A PE20120535A1 (es) 2009-03-10 2010-03-09 3-amino-2-mercaptoquinolina sustituida como modulador de kcnq2/3

Country Status (22)

Country Link
US (1) US8207342B2 (es)
EP (1) EP2406228B1 (es)
JP (1) JP5727945B2 (es)
KR (1) KR20110130461A (es)
CN (1) CN102341374A (es)
AR (1) AR075730A1 (es)
AU (1) AU2010223556B2 (es)
BR (1) BRPI1009519A2 (es)
CA (1) CA2754943A1 (es)
CL (1) CL2011002160A1 (es)
CO (1) CO6410291A2 (es)
EC (1) ECSP11011346A (es)
ES (1) ES2436365T3 (es)
IL (1) IL214944A0 (es)
MX (1) MX2011009338A (es)
NZ (1) NZ595569A (es)
PE (1) PE20120535A1 (es)
PL (1) PL2406228T3 (es)
RU (1) RU2011140701A (es)
TW (1) TWI504395B (es)
WO (1) WO2010102779A1 (es)
ZA (1) ZA201107370B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010102778A2 (de) * 2009-03-10 2010-09-16 Grünenthal GmbH Substituierte 3-aminoisoxazolopyridine als kcnq2/3 modulatoren
TWI461197B (zh) * 2009-03-12 2014-11-21 2-mercaptoquinoline-3-carboxamide as a KCNQ2 / 3 modifier
TW201038565A (en) 2009-03-12 2010-11-01 Gruenenthal Gmbh Substituted 2-mercapto-3-aminopyridines as KCNQ2/3 modulators
TWI475020B (zh) 2009-03-12 2015-03-01 The substituted nicotine amide as a KCNQ2 / 3 modifier
AU2011295405B2 (en) 2010-08-27 2015-01-22 Grünenthal GmbH Substituted 2-oxy-quinoline-3-carboxamides as KCNQ2/3 modulators
TW201211007A (en) 2010-08-27 2012-03-16 Gruenenthal Gmbh Substituted 2-amino-quinoline-3-carboxamides as KCNQ2/3 modulators
US8653102B2 (en) 2010-08-27 2014-02-18 Gruenenthal Gmbh Substituted 2-oxo- and 2-thioxo-dihydroquinoline-3-carboxamides as KCNQ2/3 modulators
US8618129B2 (en) 2010-09-01 2013-12-31 Gruenenthal Gmbh Substituted 1-oxo-dihydroisoquinoline-3-carboxamides as KCNQ2/3 modulators
DE102018212006B3 (de) 2018-07-18 2019-10-31 Universität Greifswald Thioether als Modulatoren von Kv7.2/Kv7.3-Kanälen

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2706977A1 (de) 1977-02-18 1978-08-24 Hoechst Ag Benzoesaeuren und deren derivate sowie verfahren zu ihrer herstellung
FR2532939A1 (fr) 1982-09-13 1984-03-16 Roussel Uclaf Nouveaux derives de l'acide 4-hydroxy 3-quinoleine carboxylique substitues en 2, leur preparation, leur application comme medicament, les compositions les renfermant et les nouveaux intermediaires obtenus
DE4032147A1 (de) 1990-10-10 1992-04-16 Bayer Ag Verwendung von substituierten 2-mercaptonicotinsaeurederivaten zur bekaempfung von endoparasiten, neue substituierte 2-mercaptonicotinsaeurederivate und verfahren zu ihrer herstellung
US5583147A (en) * 1994-03-23 1996-12-10 The Dupont Merck Pharmaceutical Company Amides for the treatment of atherosclerosis
EP0716077A1 (de) 1994-12-08 1996-06-12 Ciba-Geigy Ag Aromatisch substituierte Omega-Aminoalkansäureamide und Alkansäurediamide und ihre Verwendung als Renininhibitoren
WO1996026925A1 (fr) 1995-03-01 1996-09-06 Banyu Pharmaceutical Co., Ltd. Derives de l'arylthioacetamide
US5972961A (en) * 1997-08-28 1999-10-26 Bristol-Myers Squibb Company 4-aryl-3-aminoquinoline-2-one derivatives as potassium channel modulators
DE19738616A1 (de) 1997-09-04 1999-03-11 Clariant Gmbh 4-Hydroxychinolin-3-carbonsäure-Derivate als Lichtschutzmittel
JP2002534512A (ja) 1999-01-15 2002-10-15 ノボ ノルディスク アクティーゼルスカブ 非ペプチドｇｌｐ−１アゴニスト
DE60037321D1 (de) 1999-08-04 2008-01-17 Icagen Inc Benzanilide als öffner des kaliumkanals
JP2003506388A (ja) 1999-08-04 2003-02-18 アイカゲン インコーポレイテッド 疼痛および不安症を処置または予防するための方法
US6855829B2 (en) * 2001-02-20 2005-02-15 Bristol-Myers Squibb Company 3-fluoro-2-oxindole modulators of KCNQ potassium channels and use thereof in treating migraine and mechanistically related disease
WO2002066036A1 (en) 2001-02-20 2002-08-29 Bristol-Myers Squibb Company 2,4-disubstituted pyrimidine-5-carboxamide derivatives as kcnq potassium channel modulators
US6593349B2 (en) 2001-03-19 2003-07-15 Icagen, Inc. Bisarylamines as potassium channel openers
EP1372654A4 (en) 2001-04-06 2007-10-03 Smithkline Beecham Corp QUINOLINE INHIBITORS OF HYAK1 AND HYAK3 KINASES
JP2005539081A (ja) 2002-09-17 2005-12-22 ファルマシア コーポレイション 芳香族肝臓ｘ受容体モジュレーター
CA2505195C (en) * 2002-12-23 2012-07-10 Icagen, Inc. Quinazolinones as potassium channel modulators
EP1449841A1 (en) 2003-02-19 2004-08-25 Bayer CropScience SA New fungicidal compounds
RU2006115602A (ru) 2003-10-08 2007-11-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) Модуляторы переносчиков атф-связывающих кассет
BRPI0510598A (pt) 2004-05-04 2007-11-20 Pfizer compostos de amida de aril ou heteroaril substituìdos
JP2008519814A (ja) 2004-11-12 2008-06-12 ガラパゴス・ナムローゼ・フェンノートシャップ プロテインキナーゼ酵素の活性部位と結合する窒素複素環式芳香族化合物
EP2298766B1 (en) 2005-03-03 2013-09-18 H. Lundbeck A/S Pharmaceutical formulations comrpising a substituted pyridine derivative
DE102005038947A1 (de) 2005-05-18 2006-11-30 Grünenthal GmbH Substituierte Benzo[d]isoxazol-3-yl-amin-Verbindungen und deren Verwendung in Arzneimitteln
ATE432259T1 (de) 2005-07-20 2009-06-15 Lilly Co Eli Pyridinderivate als dipeptedyl-peptidase-hemmer
EP1922311A2 (en) 2005-09-09 2008-05-21 Brystol-Myers Squibb Company Acyclic ikur inhibitors
EP1951685A1 (en) * 2005-11-18 2008-08-06 NeuroSearch A/S Novel quinazoline derivatives and their medical use
US7872128B2 (en) 2006-07-20 2011-01-18 Amgen Inc. Benzisoxazole and isoxazolo-pyridine compounds and method of use
CA2658190C (en) 2006-07-20 2013-01-29 Amgen Inc. Di-amino-substituted heterocyclic compounds and methods of use
US20100022589A1 (en) 2006-07-27 2010-01-28 Mccoull William Pyridine-3-carboxamide compounds and their use for inhibiting 11-beta-hydroxysteroid dehydrogenase
DE102006049452A1 (de) 2006-10-17 2008-05-08 Grünenthal GmbH Substituierte Tetrahydropyrolopiperazin-Verbindungen und deren Verwendung in Arzneimitteln
US8563566B2 (en) 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
KR101167773B1 (ko) 2007-08-03 2012-07-24 에프. 호프만-라 로슈 아게 Ｔａａｒ１ 리간드로서의 피리딘카복스아마이드 및 벤즈아마이드 유도체
US8299123B2 (en) 2007-10-19 2012-10-30 Boehringer Ingelheim International Gmbh CCR10 antagonists
WO2010102778A2 (de) * 2009-03-10 2010-09-16 Grünenthal GmbH Substituierte 3-aminoisoxazolopyridine als kcnq2/3 modulatoren
TW201038565A (en) * 2009-03-12 2010-11-01 Gruenenthal Gmbh Substituted 2-mercapto-3-aminopyridines as KCNQ2/3 modulators
TWI475020B (zh) * 2009-03-12 2015-03-01 The substituted nicotine amide as a KCNQ2 / 3 modifier
TWI461197B (zh) * 2009-03-12 2014-11-21 2-mercaptoquinoline-3-carboxamide as a KCNQ2 / 3 modifier

Also Published As

Publication number Publication date
EP2406228A1 (de) 2012-01-18
CA2754943A1 (en) 2010-09-16
NZ595569A (en) 2012-11-30
IL214944A0 (en) 2011-11-30
AU2010223556B2 (en) 2015-01-29
TW201036610A (en) 2010-10-16
AR075730A1 (es) 2011-04-20
CN102341374A (zh) 2012-02-01
MX2011009338A (es) 2011-09-27
PL2406228T3 (pl) 2014-02-28
ECSP11011346A (es) 2011-10-31
BRPI1009519A2 (pt) 2016-03-15
JP2012521966A (ja) 2012-09-20
TWI504395B (zh) 2015-10-21
EP2406228B1 (de) 2013-09-18
ZA201107370B (en) 2012-07-25
US8207342B2 (en) 2012-06-26
CL2011002160A1 (es) 2012-08-17
KR20110130461A (ko) 2011-12-05
US20100234421A1 (en) 2010-09-16
WO2010102779A1 (de) 2010-09-16
RU2011140701A (ru) 2013-04-20
ES2436365T3 (es) 2013-12-30
AU2010223556A1 (en) 2011-11-03
CO6410291A2 (es) 2012-03-30
JP5727945B2 (ja) 2015-06-03

Similar Documents

Publication Publication Date Title
PE20120535A1 (es) 3-amino-2-mercaptoquinolina sustituida como modulador de kcnq2/3
CY1118104T1 (el) Νεα κυτταροστατικα νουκλεοζιδια 7-αποαζαπουρινης
PE20150400A1 (es) Benzamidas n-sustituidas y su uso en el tratamiento del dolor
CY1119049T1 (el) Υποκατεστημενα πυρρολιδινο-2-καρβοξαμιδια
DK2134691T3 (da) Quinolinonderivativer som parp- og tank-inhibitorer
PH12017501192B1 (en) Certain amino-pyridazines, compositions thereof, and methods of their use
EA201290397A1 (ru) 1,3,4-оксадиазол-2-карбоксамидное соединение
EA201100875A1 (ru) Новые пиразол-4-n-алкоксикарбоксамиды в качестве микробиоцидов
EA200901609A1 (ru) Амиды пиразолкарбоновой кислоты, применимые в качестве микробиоцидов
MY160424A (en) Substituted pyrrolidine-2-carboxyamides.
GEP201706728B (en) Noxious organism control agent
EA201100037A1 (ru) Органические соединения
EA201001257A1 (ru) Модуляторы ampk (амф-активируемой протеинкиназы)
EA201100503A1 (ru) Глюкозидные производные и их применения
ATE459622T1 (de) Tropanverbindungen
PT2310356E (pt) Derivados de adamantildiamida e a sua utilização
EA201170154A1 (ru) Производные пиридинопиридинонов, способ их получения и применение в терапии
RS54485B1 (en) C7-FLUORO SUBSTITUTED TETRACYCLINE UNITS
CR10955A (es) Nuevo procedimiento de sintesis de la agomelatina
IN2012DN00765A (es)
RS53900B1 (en) CRYSTAL FORMS OF HYDROCHLORIDE SALTS (4A-R, 9A-S) -1- (1H-BENZOIMIDAZOL-5-CARBONYL) -2,3,4,4A, 9,9A-HEXAHIDRO-1H-INDENO [2,1-B] PIRIDIN-6-CARBONITRILA AND THEIR USE AS A HSD INHIBITOR 1
CR10960A (es) Nuevo procedimiento de sintesis de la agomelatina
RS54488B1 (en) NALOXOL-POLYETHYLENE GLYCOL CRYSTAL CONJUGATE
EA201200602A1 (ru) Индазолы и пиразолопиридины в качестве антагонистов рецептора ccr1
CR11360A (es) Benzotiazoles como moduladores del receptor de grelina

Legal Events

Date Code Title Description
FA Abandonment or withdrawal